Oncosec Medical (ONCS) Tops Q2 EPS by 4c

Oncosec Medical (NASDAQ: ONCS) reported Q2 EPS of ($0.42), $0.04 better than the analyst estimate of ($0.46).

OncoSec's development milestones and value drivers over the next 12 months include:

• Complete patient enrollment in the Phase II combination trial of ImmunoPulse™ IL-12 with anti-PD-1 in patients with metastatic melanoma
• Present preliminary clinical and biomarker data from our Phase II melanoma clinical trials at upcoming scientific conferences; data to be used to finalize development strategy
• Identify novel "multi-gene" combination ImmunoPulse™ candidate
• Complete triple negative breast cancer pilot study as proof-of-concept and present interim data
• Present data from our preclinical programs, including studies with our existing industry collaborators

For earnings history and earnings-related data on Oncosec Medical (ONCS) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• COPT Defense Properties (CDP) Reports In-Line Q1 EPS; offers guidance
• USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c